Teriparatide (Teriparatide) Patent Expiration, LOE Window & CMS Spending
Teriparatide (Teriparatide) by Almaject: Off-Patent Genericized (AB Competition), 4 AB generics, $231.0M 2024 CMS Part D & Medicaid spend, and $3,798 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Almaject |
| FDA Application & Pathway | N218771 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $231.0M |
| 2024 Medicare Part D Spend | $212.6M |
| 2024 Medicaid Spend | $18.4M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,798 intro WAC) |